IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extranodal NK/T Cell Lymphoma, Nasal Type
Conditions
Extranodal NK/T Cell Lymphoma, Nasal Type
Trial Timeline
Nov 24, 2020 → Feb 28, 2023
NCT ID
NCT04602065About IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody) is a phase 1/2 stage product being developed by Innovent Biologics for Extranodal NK/T Cell Lymphoma, Nasal Type. The current trial status is terminated. This product is registered under clinical trial identifier NCT04602065. Target conditions include Extranodal NK/T Cell Lymphoma, Nasal Type.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04602065 | Phase 1/2 | Terminated |
Competing Products
8 competing products in Extranodal NK/T Cell Lymphoma, Nasal Type
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| High dose of methotrexate + Gemcitabine + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| Camrelizumab | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1210 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 33 |
| carfilzomib | Amgen | Phase 1 | 32 |